Navigation Links
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
Date:10/23/2008

Details to be presented at NACFC and ICAAC/IDSA meetings this week

SAN DIEGO, Oct. 23 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced additional clinical and preclinical results with MP-376, the company's novel formulation of levofloxacin inhaled solution delivered by an Investigational eFlow Nebulizer System for use in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Clinical results show that aerosol dosing of MP-376 was well tolerated at all dose levels tested after 14 days of dosing. Encouraging signs of drug activity were also observed in this trial. New preclinical results demonstrate that MP-376 has potent activity against Pseudomonas aeruginosa (P. aeruginosa) infection under a wide array of conditions, avoids resistance development when used at high concentrations achievable with aerosol dosing and has anti-inflammatory properties in pulmonary tissues in addition and unrelated to its antibacterial effects. Detailed results are being presented at the North American Cystic Fibrosis Conference (NACFC) and ICAAC/IDSA meetings taking place this week in Orlando, Florida and Washington, D.C., respectively.

Clinical Results

The clinical results being presented at NACFC are from a Phase 1b safety, tolerability and pharmacokinetic (PK) study performed in 40 CF patients with stable disease at 11 U.S. clinical sites (Mpex 203). The study was a placebo-controlled, dose escalation trial to analyze the effects of 14 days of dosing at three different dose levels of MP-376 when administered by inhalation using an Investigational eFlow Nebulizer System.

All patients were required to be culture positive for P. aeruginosa at baseline. P. aeruginosa is a bacterial pathogen that is a leading cause of morbidity in CF patients. The great majority of CF patients over the age of 18 are chronically infected with this pathogen and chronic infection has been shown to lead to acute exacerbations and subsequent loss of l
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
10. Critical Pharmaceuticals Enter Sustained Release hGH Arena
11. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... LOVELAND, Colo. , May 24, 2013  Heska Corporation ... veterinary diagnostic and specialty products, announced today that Dr. ... executive officer, and Jason Napolitano , executive ... Second Annual Marcum MicroCap Conference, which is being held May ... at the Grand Hyatt Hotel. The Company,s ...
(Date:5/24/2013)... 2013 China Biologic Products, Inc. (Nasdaq: CBPO, ... plasma-based biopharmaceutical company in China , ... a public announcement issued by Shanghai RAAS Blood Products ... Shenzhen Stock Exchange, that on May 21, 2013, Ms. ... one of the shareholders of the Company, and her ...
(Date:5/24/2013)... 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... in the Deutsche Bank Health Care Conference to be ... Mr. Adrian Adams , Chief Executive ... of the Company and its product pipeline at 12:00 ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:5/24/2013)... to the new market research report “Micro Irrigation System ... by MarketsandMarkets, global micro irrigation system market expected to ... 2010 and is expected to reach $3,414.7 million by ... to 2016. , Browse:, , 150 ... 370 pages and in-depth Table Of Content ...
(Date:5/24/2013)... 24, 2013 Just about any bodyweight training ... Whitfield, a trainer based in Dallas, GA that uses a ... one pushup that is not used enough. , “The ... the standard pushup more challenging. By keeping your hands on ... the abs are being worked much harder than a standard ...
(Date:5/24/2013)... 2013 Child safety expert and author, ... end-of-year gifts for teachers that can "show appreciation for ... Van der Zande is the founder of Kidpower, a ... whose mission is to help people create cultures ... have an incredible impact on the emotional and physical ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Patients who ... more likely to suffer from gastroesophageal reflux disease or ... reported in a study published today. , The article, ... Proximal Exposure as Measured by Hypopharyngeal Multichannel Intraluminal Impedance” ... could be of great importance to individuals who live ...
(Date:5/24/2013)... BroadConnect Telecom, the nation’s leading ... IT security solutions, present small to midsized businesses ... more than fifty percent (when compared to conventional ... Bundle Pricing. BroadConnect’s hosted Voice solutions are putting ... , Starting today, until the end of June ...
Breaking Medicine News(10 mins):Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 2Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 3Health News:Kidpower's 7 Tips For Parents To Find Meaningful End-Of-Year Gifts for Your Child’s Teacher 4Health News:West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough 2Health News:BroadConnect Is Offering New Hosted PBX Bundle Pricing for New Customers, Eliminating VoIP Adoption Barriers 2
... has come out with a warning to consumers and health care ... Teq, to infants. There is reportedly a risk of intussusception. ... months of age, in three doses as an optional vaccine to ... at times, fatal. , The reporting of 28 cases ...
... lung cancer has won $ 1 million in a lottery. Wayne ... inoperable lung cancer. ,Doctors have given him a year ... he has won this lottery. But the irony that is accompanying ... annual installments over twenty years. ,Schenk is a chain ...
... University in Chicago claim that men who have undergone ... type// of dementia. This study was published in Cognitive ... on 106 men. Out of this, 25 developed a ... undergone vasectomy. According to the chief scientist of this ...
... A new study suggests that patients who develop ... family history includes alcohol// abuse may be more ... effect of medications used to treat their condition. ... shopping, hypersexuality, binge eating and pathological gambling—have been ...
... sclerosis (MS) for 10 years and have few of the disabling ... and that their symptoms will likely not ever occur to the ... that unfortunately this may not be correct. ,After ... whose MS was benign at 10 years, according to the study. ...
... screening has increased, there are still significant disparities in ... of these disparities are by ethnicity, sex, age, education ... the third most common cancer affecting men and women ... in 2005, according to background information in the article. ...
Cached Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2
... of Surgical Access ...unlike any trocar system ... system is actually four systems in one ... and clinically adaptive to all of your ... and bladed or dilating tip styles, OnePort™ ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
... ENDOPATH Dilating Tip Trocar is a full-featured trocar ... a spring-loaded blade shield. The shield is designed ... internal structures from puncture or laceration once the ... integrated stability sleeve option is designed to enhance ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: